During the last session, Prime Medicine Inc (NASDAQ:PRME)’s traded shares were 2.29 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.32, reflecting an intraday loss of -7.04% or -$0.1. The 52-week high for the PRME share is $8.27, that puts it down -526.52 from that peak though still a striking 15.15% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $173.13M, and the average trade volume was 1.46 million shares over the past three months.
Prime Medicine Inc (PRME) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.18. PRME has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Prime Medicine Inc (NASDAQ:PRME) trade information
Prime Medicine Inc (PRME) registered a -7.04% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.04% in intraday trading to $1.32, hitting a weekly high. The stock’s 5-day price performance is -24.14%, and it has moved by 14.78% in 30 days. Based on these gigs, the overall price performance for the year is -75.56%.
The consensus price target of analysts on Wall Street is $17, which implies an increase of 92.24% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $23 respectively. As a result, PRME is trading at a discount of -1642.42% off the target high and -809.09% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -124.13%. While earnings are projected to return 23.96% in 2025, the next five years will return 14.23% per annum.
PRME Dividends
Prime Medicine Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 6.13 million shares, is of ARK INVESTMENT MANAGEMENT LLC’s that is approximately 5.1404% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $31.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Prime Medicine Inc (PRME) shares are ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that ARK ETF Trust-ARK Genomic Revolution ETF owns about 2.5 shares. This amounts to just over 1.91 percent of the company’s overall shares, with a $3.3 million market value. The same data shows that the other fund manager holds slightly less at 2.1, or about 1.60% of the stock, which is worth about $2.77 million.
